Shandong Sito Bio-technology Past Earnings Performance
Past criteria checks 0/6
Shandong Sito Bio-technology has been growing earnings at an average annual rate of 24.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.3% per year.
Key information
24.5%
Earnings growth rate
24.0%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 7.3% |
Return on equity | -0.3% |
Net Margin | -0.07% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Shandong Sito Bio-technology (SZSE:300583) Is Taking Some Risk With Its Debt
Dec 24There's Reason For Concern Over Shandong Sito Bio-technology Co., Ltd.'s (SZSE:300583) Massive 26% Price Jump
Nov 15Shandong Sito Bio-technology Co., Ltd.'s (SZSE:300583) 33% Share Price Surge Not Quite Adding Up
Sep 27Why We're Not Concerned Yet About Shandong Sito Bio-technology Co., Ltd.'s (SZSE:300583) 26% Share Price Plunge
Jun 06There May Be Reason For Hope In Shandong Sito Bio-technology's (SZSE:300583) Disappointing Earnings
May 05Risks Still Elevated At These Prices As Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) Shares Dive 30%
Apr 16Revenue & Expenses Breakdown
How Shandong Sito Bio-technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,122 | -1 | 128 | 55 |
30 Jun 24 | 1,183 | -1 | 145 | 59 |
31 Mar 24 | 1,189 | 33 | 139 | 55 |
31 Dec 23 | 1,280 | 46 | 145 | 55 |
30 Sep 23 | 1,302 | 62 | 137 | 60 |
30 Jun 23 | 1,340 | 70 | 129 | 58 |
31 Mar 23 | 1,393 | 45 | 130 | 57 |
01 Jan 23 | 1,312 | 42 | 127 | 50 |
30 Sep 22 | 1,253 | 46 | 128 | 47 |
30 Jun 22 | 1,215 | 50 | 121 | 44 |
31 Mar 22 | 1,184 | 54 | 124 | 46 |
01 Jan 22 | 1,203 | 36 | 125 | 50 |
30 Sep 21 | 1,070 | -99 | 129 | 54 |
30 Jun 21 | 1,044 | -124 | 133 | 54 |
31 Mar 21 | 963 | -161 | 122 | 49 |
31 Dec 20 | 913 | -180 | 130 | 45 |
30 Sep 20 | 904 | -77 | 133 | 50 |
30 Jun 20 | 879 | -45 | 122 | 53 |
31 Mar 20 | 901 | -1 | 114 | 57 |
31 Dec 19 | 966 | 55 | 86 | 56 |
30 Sep 19 | 992 | 110 | 85 | 35 |
30 Jun 19 | 1,071 | 120 | 75 | 30 |
31 Mar 19 | 1,099 | 129 | 76 | 39 |
31 Dec 18 | 1,052 | 126 | 76 | 39 |
30 Sep 18 | 1,129 | 146 | 70 | 49 |
30 Jun 18 | 1,040 | 134 | 59 | 60 |
31 Mar 18 | 923 | 117 | 61 | 38 |
31 Dec 17 | 786 | 92 | 54 | 32 |
30 Sep 17 | 690 | 74 | 46 | 17 |
30 Jun 17 | 611 | 76 | 62 | 0 |
31 Mar 17 | 624 | 99 | 55 | 0 |
31 Dec 16 | 568 | 101 | 55 | 0 |
30 Sep 16 | 562 | 115 | 100 | 0 |
31 Dec 15 | 668 | 187 | 56 | 0 |
31 Dec 14 | 521 | 166 | 35 | 0 |
31 Dec 13 | 284 | 42 | 18 | 0 |
Quality Earnings: 300583 is currently unprofitable.
Growing Profit Margin: 300583 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300583 is unprofitable, but has reduced losses over the past 5 years at a rate of 24.5% per year.
Accelerating Growth: Unable to compare 300583's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300583 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 300583 has a negative Return on Equity (-0.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 01:12 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Sito Bio-technology Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ban Wang | Minsheng Securities Co. |